It also contributes to good liver function* *Results may vary
There was also no increase in the risk of pancreatic, breast, or prostate cancer
The growing prevalence of obesity and associated comorbidities, such as diabetes and cardiovascular disorders, has propelled the demand for GLP-1 receptor agonists
This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. The Obesity Action Coalition (OAC), The Obesity Society (TOS), and The Obesity Medicine Association (OMA) have released a statement expressing their concerns for patients using the compounded GLP-1 alternatives
However, supplementation can have potential side effects
One single IV infusion of VERVE-102 permanently lowered LDL cholesterol by 62%